Actively Recruiting
Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy
Led by Insel Gruppe AG, University Hospital Bern · Updated on 2024-03-27
80
Participants Needed
1
Research Sites
159 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this observational study is to learn about vaccine immunity in patients with B-cell malignancies treated by chimeric antigen receptor T-cell therapies (CAR-T). The main questions it aims to answer are: * Do CAR-T cell therapy recipients lose vaccine protection against common vaccine-preventable pathogens * Are current re-vaccination recommendations sufficient in restoring vaccine-protection * Is this restored vaccine-protection after CAR-T cell therapy lost faster than usual * Do clinical or immunological factors predict vaccine response after CAR-T cell therapy
CONDITIONS
Official Title
Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient is 18 years old or older
- Diagnosed with a B-cell malignancy such as B-cell acute lymphoblastic leukemia (ALL), B-cell non-Hodgkin lymphoma (NHL), follicular lymphoma (FL), mantle cell lymphoma (MCL), or multiple myeloma (MM)
- Planned to receive CAR-T cell therapy
- Provided written informed consent
You will not qualify if you...
- Previous or already started CAR-T cell therapy
- Younger than 18 years old
- Did not provide consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital Bern
Bern, Switzerland, 3010
Actively Recruiting
Research Team
L
Lukas N Baumann, MD
CONTACT
C
Cédric Hirzel, PD, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here